A Prospective, Randomized Comparison of Promus Everolimus-Eluting and TAXUS Liberte Paclitaxel-Eluting Stent Systems in Patients with Coronary Artery Disease Eligible for Percutaneous Coronary Intervention: The PROMISE Study

We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ung, Lee, Chan-Hee, Jo, Jung-Hwan, Lee, Hyun-Wook, Choi, Yoon-Jung, Son, Jang-Won, Lee, Sang-Hee, Park, Jong-Seon, Shin, Dong-Gu, Kim, Young-Jo, Jeong, Myung-Ho, Cho, Myung-Chan, Bae, Jang-Ho, Lee, Jae-Hwan, Kang, Tae-Soo, Jung, Kyung-Tae, Jung, Kyung-Ho, Lee, Seung-Wook, Cho, Jang-Hyun, Kim, Won, Hur, Seung-Ho, Kim, Ki-Sik, Park, Heon-Sik, Kim, Moo-Hyun, Hwang, Jin-Yong, Kim, Doo-Il, Kim, Tae-Ik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835502/
https://www.ncbi.nlm.nih.gov/pubmed/24265523
http://dx.doi.org/10.3346/jkms.2013.28.11.1609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835502/
https://www.ncbi.nlm.nih.gov/pubmed/24265523
http://dx.doi.org/10.3346/jkms.2013.28.11.1609

Ejemplares similares